Skip to main content

Table 1 Cases with Alterations of Clinical Significance Identified by BAC and Oligo aCGH.

From: Comparative analysis of copy number detection by whole-genome BAC and oligonucleotide array CGH

Pt. # Chr Band Start pos. End pos. Gain/Loss Size # of BACs # of Oligos
21637 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
21992 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
22013 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
21993 chr10 q25.2q25.3 114,306,207 114,925,368 Loss 619,161 3 36
21756 chr2 q35 219,418,281 220,060,969 Loss 642,688 2 43
22002 chr2 q37.3 239,664,393 240,400,008 Loss 735,615 3 82
22334 chr10 q25.2q25.3 114,024,053 115,677,301 Gain 1,653,248 3 53
21688 chr16 p13.11p12.3 15,056,257 16,742,812 Gain 1,686,555 3 61
21667 chr17 p12 14,052,297 15,742,271 Gain 1,689,974 3 67
21896 chr4 q35.2 189,407,487 191,133,809 Loss 1,726,322 8 147
22269 chr2 q12.3q13 107,945,041 109,784,684 Loss 1,839,643 6 102
21640 chr19 q13.42 59,272,450 61,239,237 Gain 1,966,787 8 135
22117 chr9 q33.1 118,991,777 121,063,590 Gain 2,071,813 3 67
22066 chr8 p12p11.21 38,303,146 40,515,492 Gain 2,212,346 6 104
21786 chr1 q21.1 144,973,942 147,421,814 Gain 2,447,872 5 63
22237 chr1 q21.1 144,973,942 147,421,814 Gain 2,447,872 5 63
22310 chr22 q11.21 17,299,742 19,770,655 Loss 2,470,913 13 205
22050 chr22 q11.21 17,007,819 19,770,655 Loss 2,762,836 13 208
21936 chr1 q21.1 144,973,942 147,966,185 Gain 2,992,243 5 65
21719 chr2 q31.1 169,823,689 172,870,083 Loss 3,046,394 8 119
22128 chr4 q34.3 179,065,989 182,435,119 Loss 3,369,130 3 91
22006 chr17 p11.2 16,723,071 20,145,604 Loss 3,422,533 18 311
22174 chr1 q41q42.12 221,260,860 224,709,317 Loss 3,448,457 9 178
21971 chr22 q11.23q12.2 24,025,269 28,008,109 Loss 3,982,840 3 111
22073 chr15 q11.2q13.1 21,208,177 26,194,049 Loss 4,985,872 11 281
21687 chr16 q12.2q21 51,912,655 57,173,018 Loss 5,260,363 15 261
21975 chr5 p15.2p14.3 13,514,464 18,988,928 Loss 5,474,464 3 122
21555 chr7 p22.3p22.1 153,644 6,230,285 Gain 6,076,641 32 434
21547 chr2 q24.3q31.1 168,702,606 174,842,496 Loss 6,139,890 11 226
21755 chr11 p12p11.2 37,540,680 43,940,573 Loss 6,399,893 14 298
21761 chr3 p14.1p12.3 70,738,914 77,275,908 Loss 6,536,994 6 151
22151 chr15 q11.2q13.1 18,809,804 26,194,049 Gain 7,384,245 14 331
22322 chr8 p21.3p12 22,954,212 30,630,828 Loss 7,676,616 9 224
21889 chr2 q33.1q34 202,901,021 211,366,732 Gain 8,465,711 13 281
21723 chr5 q23.1q23.3 121,487,477 130,306,377 Loss 8,818,900 4 204
22337 chr1 p36.22p36.13 9,476,880 19,436,653 Loss 9,959,773 21 436
21795 chr1 p34.2p32.3 41,201,837 55,191,500 Gain 13,989,663 17 440
20986 chr12 p13.33p12.3 84,918 17,505,135 Gain 17,420,217 46 800
21957 chr11 q23.3q25 116,478,434 134,419,382 Gain 17,940,948 40 784
21596 chr1 q25.1q32.1 173,519,967 203,663,817 Gain 30,143,850 25 814
22055 chr3 p14.1p13 71,164,161 71,958,845 Loss 794,684 3 46
21566* chr17 p13.2p13.1 6,081,457 6,904,679 Loss 823,222 3 14
21558 chr22 q13.33 48,567,185 49,517,230 Loss 950,045 6 54
21770 chr8 p23.3 202,505 1,411,517 Loss 1,209,012 5 96
22254 chr8 p23.2 2,604,280 3,966,809 Loss 1,362,529 9 140
21937 chr7 q11.23 72,404,049 73,771,409 Loss 1,367,360 10 158
21710 chr15 q13.2q13.3 28,741,818 30,186,356 Loss 1,444,538 3 64
21722 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21739 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21787 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21897* chr5 p15.2 8,511,592 9,888,817 Gain 1,377,225 34 29
21884 chrX q28 152,676,750 153,059,428 Gain 382,678 3 44
21592 chrX p22.33q28 701 154,888,083 Gain 154,887,382 325 6888
22087 chrY p11.32 262,578 57,715,879 Gain 57,453,301 49 49
22285 chrX p21.1 31,759,551 31,830,811 Loss 71,260 2 11
22244 chr22 q13.33 49,342,961 49,514,486 Loss 171,525 2 56
*additional alterations identified by oligonucleotide aCGH.